Keyphrases
Myeloproliferative Neoplasms
100%
Janus Kinase 2 (JAK2)
44%
JAK2V617F
33%
Mouse Model
22%
Blood Cell Differentiation
11%
JAK Inhibitors
11%
Normal Blood
11%
Lethality
11%
Driver mutations
11%
Downstream Effectors
11%
JAK2 Inhibitor
11%
Clinical Trials
11%
Successful Completion
11%
Progenitor Cells
11%
Cell Manufacturing
11%
Drug Resistance
11%
Small Molecular
11%
Myeloid Cells
11%
Bone Marrow Failure
11%
Medicine and Dentistry
Myeloproliferative Neoplasm
100%
Janus Kinase
44%
Blood Cell
11%
Lethality
11%
Janus Kinase 2 Inhibitor
11%
Bone Marrow Disease
11%
Janus Kinase Inhibitor
11%
Myeloid Cell
11%
Side Effect
11%
Clinical Trial
11%
Progenitor Cell
11%
Drug Resistance
11%
Cell Development
11%
Pharmacology, Toxicology and Pharmaceutical Science
Myeloproliferative Neoplasm
100%
Janus Kinase
44%
Mouse Model
22%
Bone Marrow Disease
11%
Clinical Trial
11%
Janus Kinase 2 Inhibitor
11%
Lethality
11%
Side Effect
11%
Janus Kinase Inhibitor
11%
Drug Resistance
11%